The General Hospital Corporation

United States of America

Back to Profile

1-100 of 2,108 for The General Hospital Corporation Sort by
Query
Patent
World - WIPO
Excluding Subsidiaries
Aggregations Reset Report
Date
New (last 4 weeks) 21
2024 June (MTD) 6
2024 May 22
2024 April 25
2024 March 9
See more
IPC Class
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 148
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons 140
A61P 35/00 - Antineoplastic agents 126
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 91
G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor 65
See more
Found results for  patents
  1     2     3     ...     22        Next Page

1.

CORNEAL FILLER

      
Application Number US2023083210
Publication Number 2024/124189
Status In Force
Filing Date 2023-12-08
Publication Date 2024-06-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Li, Xiaolei
  • Evans, Conor, L.
  • Birngruber, Reginald
  • Anderson, Richard, R.
  • Parshad, Badri
  • Buhl, Lara
  • Apiou, Gabriela

Abstract

Disclosed are compositions, systems, and methods for treating hyperopia and presbyopia without tissue removal to increase the refractive power of the cornea. A polymer conjugate is provided, which can be used as an injectable filler material for comeal implant. In particular embodiments, the polymer conjugate comprises an aldehy de hyaluronic acid conjugated with a poly ether through a-CH=N- bond.

IPC Classes  ?

  • A61L 27/20 - Polysaccharides
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
  • C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof

2.

MULTI-FIBER CATHETER PROBE FOR MULTI-PARAMETRIC OPTICAL COHERENCE TOMOGRAPHY

      
Application Number US2023083182
Publication Number 2024/124171
Status In Force
Filing Date 2023-12-08
Publication Date 2024-06-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cannon, Taylor
  • Shishkov, Milen
  • Bouma, Brett, E.
  • Uribe-Patarroyo, Néstor
  • Villiger, Martin

Abstract

A multi-resolution OCT imaging system for improved tissue scattering property characterization. The system includes a probe with one or more optical fibers and optical elements for scanning a sample with two or more beams. A single fiber probe includes a diffractive element for splitting a single light beam from the fiber optic into two or more beams. The multiple beams entering and reflecting from the tissue differ in path length and numerical aperture (NA) to provide different resolution imaging for determining multiple scattering in the tissue.

IPC Classes  ?

  • G01B 9/02091 - Tomographic interferometers, e.g. based on optical coherence
  • A61B 5/027 - Measuring blood flow using electromagnetic means, e.g. electromagnetic flow meter using catheters
  • G01B 9/02017 - Interferometers characterised by the beam path configuration with multiple interactions between the target object and light beams, e.g. beam reflections occurring from different locations

3.

HISTONE DEACETYLASE INHIBITORS

      
Application Number US2023082358
Publication Number 2024/123700
Status In Force
Filing Date 2023-12-04
Publication Date 2024-06-13
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wang, Changning
  • Bai, Ping
  • Zhang, Can
  • Shen, Shiqian
  • Tanzi, Rudolph E.

Abstract

This disclosure relates to certain compounds that are inhibitors of histone deacetylases (HDACs), as well as compositions thereof and methods of using such compounds to treat diseases, such as those described herein.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 35/00 - Antineoplastic agents
  • C07C 15/02 - Monocyclic hydrocarbons
  • C07C 237/28 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton

4.

ASSESSING RISK FOR MULTIPLE MYELOMA PRECURSOR DISEASE PROGRESSION

      
Application Number US2023081160
Publication Number 2024/118504
Status In Force
Filing Date 2023-11-27
Publication Date 2024-06-06
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Trippa, Lorenzo
  • Getz, Gad
  • Ghobrial, Irene M.
  • Cowan, Anna
  • Ferrari, Federico
  • Freeman, Samuel

Abstract

Techniques for estimating a risk that a condition of a patient with a multiple myeloma (MM) precursor disease such as MGUS or SMM will progress into MM.

IPC Classes  ?

  • G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G16B 40/30 - Unsupervised data analysis
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

5.

CALCULATION OF GASEOUS BIOMARKER CONCENTRATION IN TISSUE VIA AN INVERSE BOUNDARY PROBLEM

      
Application Number US2023081512
Publication Number 2024/118707
Status In Force
Filing Date 2023-11-29
Publication Date 2024-06-06
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Cascales Sandoval, Juan
  • Evans, Conor, L.

Abstract

Systems and methods for determining a level of a parameter of an analyte: cause a photon source to direct photons at a probe sensitive to the analyte and excite the probe to emit light; receive optical data from a photodetector based on the light emitted from the probe; determine, based on optical data from the photodetector, a difference between a first level of a parameter of the analyte at a first location adjacent a first surface of the probe and an intermediate level of the parameter of the analyte at an intermediate location between the first location and a second location adjacent a second surface of the probe; and determine a second level of the parameter of the analyte adjacent the second surface of the probe based on the difference between the first level of the parameter of the analyte and the intermediate level of the parameter of the analyte.

IPC Classes  ?

  • G01J 1/58 - Photometry, e.g. photographic exposure meter using luminescence generated by light
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
  • G01J 3/02 - Spectrometry; Spectrophotometry; Monochromators; Measuring colours - Details

6.

SYSTEM FOR AND METHOD OF EYE TRACKING

      
Application Number US2023082298
Publication Number 2024/119173
Status In Force
Filing Date 2023-12-04
Publication Date 2024-06-06
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kong, Xue-Jun
  • Kwong, Kenneth K.
  • Wang, Raymond K.

Abstract

Systems and methods for identifying a change in visual fixation of an individual over time implement and/or include: collecting a data set collected indicative of an individual's visual fixation with respect to a visual stimulus as determined by an eye tracking device; extracting one or more eye tracking metrics from the data set; generating, via software executing on a processor, an indication of at least one of a diagnosis or subtype indication based on the one or more eye tracking metrics.

IPC Classes  ?

  • A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
  • G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]

7.

WIRELESS THERMAL DETECTION CAPSULE

      
Application Number US2023080662
Publication Number 2024/112736
Status In Force
Filing Date 2023-11-21
Publication Date 2024-05-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Tearney, Guillermo
  • Magley, Daniel

Abstract

An apparatus for detecting gastrointestinal pathology, including: a capsule including at least one temperature sensor, the capsule being configured to be swallowed by a subject, and the at least one temperature sensor being configured to circumferentially detect heat emitted by a tissue of the subject.

IPC Classes  ?

  • A61B 5/07 - Endoradiosondes
  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters

8.

INDUCIBLE CELL SUICIDE SWITCHES AND THEIR USE IN CELL AND GENE THERAPIES

      
Application Number US2023080756
Publication Number 2024/112795
Status In Force
Filing Date 2023-11-21
Publication Date 2024-05-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Jan, Max
  • Manguso, Robert T
  • Maus, Marcela V
  • Sarkar, Ditsa

Abstract

Provided herein are small-molecule inducible cell suicide switches and their use in cell and gene therapies.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 19/00 - Hybrid peptides
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/86 - Viral vectors

9.

CYANINE-BASED FLUOROPHORES

      
Application Number US2023079600
Publication Number 2024/107699
Status In Force
Filing Date 2023-11-14
Publication Date 2024-05-23
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
  • Choi, Hak Soo
  • Kang, Homan
  • Henary, Maged M.

Abstract

The present application provides compounds and methods for structure-inherent targeting and intraoperative imaging of cancerous tumors.

IPC Classes  ?

  • C09B 23/06 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups three CH groups, e.g. carbocyanines
  • A61K 49/00 - Preparations for testing in vivo

10.

IMAGING AGENTS FOR DETECTING CD206+ MACROPHAGES

      
Application Number US2023079802
Publication Number 2024/107828
Status In Force
Filing Date 2023-11-15
Publication Date 2024-05-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wang, Cuihua
  • Chen, John W.

Abstract

This disclosure relates to imaging agents such as compounds of Formula (I): or pharmaceutically acceptable salts thereof, for the detection of CD206+in vitroin vivoin vivo, wherein the variables are described herein.

IPC Classes  ?

  • A61K 49/10 - Organic compounds
  • C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
  • C07H 23/00 - Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

11.

MINIMAL VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES

      
Application Number US2023080020
Publication Number 2024/107959
Status In Force
Filing Date 2023-11-16
Publication Date 2024-05-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are minimal virus-like particles (mVLPs), comprising a membrane comprising a phospholipid bilayer with one or more ectodomain-truncated VSV envelope glycoproteins on the external side; and a biomolecule cargo disposed in the core of the mVLP on the inside of the membrane. Preferably, the mVLPs do not comprise a protein from viral gag, pro, pol, or other viral proteins that reside inside of enveloped particles. Also described are methods of use of the mVLPs for delivery of the biomolecule cargo to cells.

IPC Classes  ?

  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K 14/145 - Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
  • C12N 15/86 - Viral vectors
  • C12N 9/22 - Ribonucleases
  • A61P 35/00 - Antineoplastic agents

12.

MINIMAL HUMAN-DERIVED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES

      
Application Number US2023080086
Publication Number 2024/108001
Status In Force
Filing Date 2023-11-16
Publication Date 2024-05-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are virus-like particles (VLPs) and minimal human-derived virus-like particles (mhVLPs), comprising a membrane comprising a phospholipid bilayer with one or more human-derived envelope glycoproteins (env) on the external side. Optionally, a biomolecule cargo is disposed in the core of the VLP or mhVLP on the inside of the membrane. Preferably, the mhVLPs do not comprise any exogenous virally derived proteins, e.g., proteins from viral gag, pro, or pol, or other viral proteins that reside inside of enveloped particles (unless the cargo comprises the viral protein(s)). In some embodiments, the mhVLPs do not comprise any human endogenous retroviral (HERV) proteins other than the env (hENV), e.g., do not comprise gag, pol, or pro that was exogenously introduced into producer cells. In some embodiments, the VLPs include a targeting domain, either fused at the N or C terminus or internally into the hENV, or as a separate membrane-anchored targeting domain. Also described are methods of use of the VLPs or mhVLPs for delivery of the biomolecule cargo to cells.

IPC Classes  ?

13.

THERAPEUTIC EXPLOITATION OF STING CHANNEL ACTIVITY

      
Application Number US2023079800
Publication Number 2024/107827
Status In Force
Filing Date 2023-11-15
Publication Date 2024-05-23
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Hacohen, Nir
  • Liu, Bingxu
  • Carlson, Rebecca
  • Gentili, Matteo

Abstract

In certain aspects, provided herein are mutant stimulator of interferon genes (STING) polypeptides, compositions thereof and methods of using the same, wherein the mutation is within the dimerization interface of the STING, and wherein the mutation reduces the ability of the mutant STING polypeptide to mediate protein leakage across a membrane compared to a wild-type STING polypeptide.

IPC Classes  ?

  • A61K 38/00 - Medicinal preparations containing peptides
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

14.

VIRUS-LIKE PARTICLES WITH PROGRAMMABLE TROPISM AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS

      
Application Number US2023080061
Publication Number 2024/107983
Status In Force
Filing Date 2023-11-16
Publication Date 2024-05-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Cabeceiras, Peter

Abstract

Described herein are programmable tropism virus-like particles (ptVLPs), comprising a membrane comprising a phospholipid bilayer with one or more wild-type or mutant/truncated virus-derived glycoproteins on the external side. The virus-derived envelope glycoprotein(s) can optionally be fused directly to a targeting domain (e.g., a targeting peptide, single chain variable fragment (scFv), nanobody, fibronectin type 3 domain (FN3), arginylglycylaspartic acid motif (RGD), single variable domain on a heavy chain/nanobody (VHH), variable domain of new antigen receptor (VNAR), darpin, or other targeting ligand), and/or can be present in combination with a membrane-anchored targeting domain. A biomolecule cargo (preferably fused to a membrane recruitment domain, such as a Pleckstrin homology domain) can be disposed in the core of the ptVLP. Preferably, the ptVLP does not comprise a protein from any human endogenous or exogenous viral gag, pro, pol, or other viral proteins that reside inside of enveloped particles.

IPC Classes  ?

  • C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C12N 15/86 - Viral vectors

15.

SYSTEMS AND METHODS FOR UNI-TO-MULTI HAIR EXTRACTION-IMPLANTATION

      
Application Number US2023037015
Publication Number 2024/102402
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William, A.
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Systems and methods for hair transplantation include and/or implement a cartridge including a plurality of slots configured to store a plurality of hair cores; an extraction unit, comprising: a first casing including a first slot configured to releasably receive the cartridge, an extracting needle, and a first actuator configured to rotate the cartridge in a state of the cartridge being received in the first slot; and an implantation unit, comprising: a second casing including a second slot configured to releasably receive the cartridge, at least one implanting needle, and a second actuator configured to rotate the cartridge in a state of the cartridge being received in the second slot.

IPC Classes  ?

16.

APPLICATION OF COMPUTER VISION TO ENABLE REAL-TIME DIGITAL MEASUREMENTS AND TARGETING DURING ARTHROSCOPY

      
Application Number US2023078944
Publication Number 2024/102728
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PICTUS AI LLC (USA)
Inventor
  • Tanaka, Miho
  • Varadarajan, Kartik Mangudi

Abstract

A system for performing digital measurements during a medical procedure comprises: a camera to capture image data corresponding to a treatment site; a display; an instrument placed at the treatment site, the instrument including a first section having a first dimension between a first boundary and a second boundary; and a processor configured to execute instructions to: (i) receive real-time image data from the camera, the real-time image data including a portion of the instrument, (ii) detect, in the real-time image data, a profile of the instrument, (iii) identify, on the instrument, the first boundary and the second boundary, (iv) determine a real-time measurement between a first set of points of the real-time image data, the real-time measurement being determined based in part on the first dimension, (v) generate a visualization based on the real-time measurement, and (vi) display, at the display, the visualization and the real-time image data.

IPC Classes  ?

  • A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
  • G06N 20/20 - Ensemble learning
  • G06T 7/60 - Analysis of geometric attributes

17.

SYSTEMS AND METHODS FOR HAIR TRANSPLANTATION WITH SPLIT NEEDLE DEVICE

      
Application Number US2023079082
Publication Number 2024/102815
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Farinelli, William, A.
  • Korupolu, Sandeep
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Systems and methods of hair transplantation include and/or implement a device comprising a casing; an implantation unit received in the casing, the implantation unit including an implanting needle at a distal end thereof; an extraction unit received in the implantation unit, the extraction unit including an extracting needle at a distal end thereof and a first actuator portion at a proximal end thereof; and an actuation unit received in the casing and over the extraction unit, the actuation unit including a second actuator portion in cooperation with the first actuation unit and configured to selectively move the hair transplant system between a first position in which the extracting needle is at substantially the same longitudinal position as the implanting needle, and a second position in which the extracting needle is longitudinally displaced from the implanting needle in a proximal direction.

IPC Classes  ?

18.

ULTRASENSITIVE ASSAYS FOR DETECTION OF ORF1P IN BIOFLUIDS

      
Application Number US2023079148
Publication Number 2024/102852
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • THE ROCKEFELLER UNIVERSITY (USA)
  • THE JOHNS HOPKINS UNIVERSITY (USA)
Inventor
  • Taylor, Martin
  • Wu, Connie
  • Fridy, Peter, Clayton
  • Lacava, John, Paul
  • Chait, Brian, T.
  • Molloy, Kelly, Rebecca
  • Rout, Michael, Paul
  • Garden, Padric
  • Cohen, Limor
  • Walt, David, R.
  • Burns, Kathleen

Abstract

Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.

IPC Classes  ?

  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N 30/72 - Mass spectrometers

19.

SYSTEMS AND METHODS FOR LONG HAIR TRANSPLANTATION

      
Application Number US2023037023
Publication Number 2024/102407
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William, A.
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Hair transplant systems and methods include or use a casing; an extracting needle having a first groove extending longitudinally from a distal end of the extracting needle, the first groove including a notch; a lock disposed on the extracting needle and configured to selectively close at least a portion of the first groove; and a pin extending through a center of the casing and configured to cause the extracting needle to selectively take in or ej ect a hair follicle.

IPC Classes  ?

20.

N-(N-AMINOALKYL)PHENANTHRIDIUNIUM SERIES OF CHLORIDE-SENSITIVE FLUOROPHORES AND METHODS OF USE THEREOF

      
Application Number US2023078984
Publication Number 2024/102758
Status In Force
Filing Date 2023-11-07
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Normoyle, Kieran P.
  • Staley, Kevin

Abstract

Disclosed herein are compounds which are chloride-sensitive fluorophores and methods of manufacture and of use thereof.

IPC Classes  ?

  • C07D 221/10 - Aza-phenanthrenes
  • C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof

21.

SYSTEMS AND METHODS FOR HAIR TRANSPLANTATION BY SINGLE DEVICE WITH COUPLER

      
Application Number US2023079066
Publication Number 2024/102804
Status In Force
Filing Date 2023-11-08
Publication Date 2024-05-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Korupolu, Sandeep
  • Farinelli, William
  • Franco, Walfre
  • Drake, Lynn
  • Anderson, Richard, Rox

Abstract

Hair transplant systems and methods include or use an extracting unit including: a first housing extending from a proximal end portion to a distal end portion, wherein the distal end portion includes an end notch defining a seat portion and a step portion, an extracting needle, and a first coupler; an implanting unit including: a second housing, an implanting needle, and a second coupler configured to be received by the first coupler; and a resilient element disposed between the extracting unit and the implanting unit to provide a biasing force to cause the hair transplant system to move between an extraction state and an implantation state. In the extraction state, the implanting unit is positioned within the seat portion of the distal end portion, and in the implantation state, the implanting unit is positioned on the step portion of the distal end portion.

IPC Classes  ?

22.

SUBCUTANEOUS MULTICHANNEL WIRELESS ELECTROENCEPHALOGRAPHY SYSTEM FOR CHRONIC HOME USE

      
Application Number US2023078505
Publication Number 2024/097865
Status In Force
Filing Date 2023-11-02
Publication Date 2024-05-10
Owner
  • BROWN UNIVERSITY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Nurmikko, Arto
  • Lee, Jihun
  • Lee, Ah-Hyun
  • Cash, Sydney, S.

Abstract

A system comprises one or more sensor devices for subcutaneous electroencephalography where each sensor device includes a flexible biocompatible polymer sensor strip adapted to be inserted into a cranial subdermal space and including a plurality of electrodes. The strip includes a microchip responsive to each of the electrodes and comprising a multi-channel integrated circuit system-on-chip with a wireless transceiver, a low-noise neural amplifier, a unique network address, and RF energy harvesting microcircuits. In one embodiment, the sensor strip is no more than about 1 mm wide, at least about 5 cm long, and no more than about 300 μm thick. An external transceiver is disposed on the exterior of the subject's skin near one or more sensor devices in secure wireless communication with the respective wireless transceivers comprised in the sensor devices microchips. The system is configured to communicate using a network communication protocol, such as time division multiple access or code division multiple access.

IPC Classes  ?

  • A61B 5/293 - Invasive
  • A61B 5/37 - Intracranial electroencephalography [IC-EEG], e.g. electrocorticography [ECoG]
  • A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
  • A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]

23.

SYSTEMS AND METHODS FOR SUPERVISED REMOTE IMAGING-GUIDED INTERVENTION

      
Application Number US2023036541
Publication Number 2024/097260
Status In Force
Filing Date 2023-10-31
Publication Date 2024-05-10
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Johnson, Matthew R.
  • Brattain, Laura J.
  • Telfer, Brian A.
  • Gjesteby, Lars A.
  • Werblin, Joshua S.
  • Delosa, Nancy D.
  • Samir, Anthony E.
  • Pierce, Theodore T.

Abstract

A method for remote intervention for a subject includes acquiring an image of a region of interest of the subject using an interventional device positioned on the subject and an image acquisition system. The region of interest includes a target structure and the subject is located at a first site. The method further includes analyzing the acquired image using an image analysis module to identify and label the target structure in the region of interest and transmitting the labelled image from the first site to a second site for expert review. The second site is remote from the first site. The method further includes receiving a command signal at the first site from the second site where the command signal is generated based on the expert review of the labelled image and configured to control an action of the interventional device. In some embodiments, the method may further include analyzing the acquired image to determine a pathway to the vessel that avoids critical structures.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]

24.

METHOD AND DEVICE TO PREDICT EXERCISE PEAK VO2, CARDIOVASCULAR OUTCOMES AND FUTURE DEATH USING ECG DEEP LEARNING MODELS

      
Application Number US2023036750
Publication Number 2024/097390
Status In Force
Filing Date 2023-11-03
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Lubitz, Steven
  • Ellinor, Patrick
  • Batra, Puneet
  • Khurshid, Shaan
  • Diamant, Nathaniel
  • Guseh, James, Sawalla
  • Friedman, Samuel

Abstract

2PEAK2 PEAK2PEAKPEAK to the first computing device associated or a device associated with the subject.

IPC Classes  ?

  • A61B 5/083 - Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
  • A61B 5/346 - Analysis of electrocardiograms
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

25.

SYSTEM AND METHOD FOR CONTROLLING AGAINST OR TREATING OF TYMPANOSTOMY TUBE INFECTIONS

      
Application Number US2023078805
Publication Number 2024/098056
Status In Force
Filing Date 2023-11-06
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • BOSTON MEDICAL CENTER CORPORATION (USA)
Inventor
  • Dai, Tianhong
  • Pelton, Stephen, I
  • Anderson, R., Rox
  • Sabharwal, Vishakha

Abstract

Aspects of the present disclosure provide a system for preventing or treating tympanostomy tube infections. The system includes an ear tube that is configured to be placed within an ear of a subject. The ear tube has a shaft that extends from a proximal end to a distal end, and a lumen extends through the shaft. The ear tube also includes a flange extending from the shaft at the proximal end and a flange extending from the shaft at the distal end. The system further includes an optical waveguide that is configured to deliver antimicrobial light to a surface area of the ear tube while placed within the ear of the subject. The optical waveguide includes an optical fiber that is configured to deliver the antimicrobial light and a fiber collimator that is configured to guide the antimicrobial light towards the surface area of the ear tube.

IPC Classes  ?

26.

INTRA-OCULAR OPTICAL COHERENCE TOMOGRAPHY APPARATUS AND METHOD FOR VITREORETINAL SURGERY

      
Application Number US2023078321
Publication Number 2024/097733
Status In Force
Filing Date 2023-11-01
Publication Date 2024-05-10
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MASSACHUSETTS EYE AND EAR INFIRMARY (USA)
Inventor
  • Baldwin, Grace, Elizabeth
  • Tearney, Guillermo
  • Miller, John
  • Garcia Coleto, Andres
  • Doherty, Forrest, Nicholas
  • Romano, Francesco

Abstract

An optical probe, including; an optical fiber coupled to a moveable actuator, the moveable actuator being configured to direct light emitted from the optical fiber at a plurality of varying angles; and a relay lens distal to the moveable actuator and configured to receive light emitted from the optical fiber and direct the received light at a sample.

IPC Classes  ?

  • A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
  • A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
  • G01B 9/02 - Interferometers
  • G01J 3/443 - Emission spectrometry
  • G02B 3/00 - Simple or compound lenses

27.

SYSTEM AND METHOD FOR CHARACTERIZING AND TRACKING AGING, RESILIENCE, COGNITIVE DECLINE, AND DISORDERS USING BRAIN DYNAMIC BIOMARKERS

      
Application Number US2023078239
Publication Number 2024/092277
Status In Force
Filing Date 2023-10-30
Publication Date 2024-05-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Purdon, Patrick, L.
  • He, Mingjian
  • Das, Proloy
  • Beck, Amanda

Abstract

The present application provides systems and methods of characterizing and tracking aging, resilience, dementia, and cognitive decline using brain dynamic biomarkers. The methods and system employ advanced signal processing methods to enhance the precision and quality of information coming from the EEG to detect, characterize, or track Alzheimer's Disease (AD) and Related Dementias (ADRD). These digital markers would be relevant in all stages of AD/ AD RD spanning normal cognition, mild cognitive impairment, and AD dementia. The systems and methods include extracting one or more spectral features from EEG signal data using a plurality of state-space models.

IPC Classes  ?

  • A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
  • A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
  • A61B 5/377 - Electroencephalography [EEG] using evoked responses
  • A61B 5/384 - Recording apparatus or displays specially adapted therefor
  • G06N 3/02 - Neural networks
  • G06N 20/10 - Machine learning using kernel methods, e.g. support vector machines [SVM]

28.

A SYSTEM AND METHOD FOR MEASURING ANALGESIA AND RESPONSES TO NOXIOUS OR PAINFUL STIMULI

      
Application Number US2023078249
Publication Number 2024/092280
Status In Force
Filing Date 2023-10-30
Publication Date 2024-05-02
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Purdon, Patrick, L.
  • Gutierrez Rojas, Rodrigo
  • Das, Proloy
  • Beck, Amanda

Abstract

The present disclosure provides systems and methods for providing a quantitative assessment of pain and analgesia. The systems and methods provide, direct, objective, assessments of pain and the reduction of pain from different drugs or therapeutics. As a result, such systems and methods provide feedback for adjusting drug or therapeutics to a desired endpoint and could be used in the process of discovering or developing novel drugs or therapeutics. The system and methods include a novel state space evoked response potential (SS-ERP) model for extracting ERP signals from electroencephalography (EEG) data from a patient. The disclosed systems and methods enable the measurement of pain and pain therapeutic effects in an individualized manner.

IPC Classes  ?

  • A61B 5/369 - Electroencephalography [EEG]
  • A61B 5/372 - Analysis of electroencephalograms
  • A61B 5/375 - Electroencephalography [EEG] using biofeedback
  • A61B 5/377 - Electroencephalography [EEG] using evoked responses
  • A61M 16/01 - Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes specially adapted for anaesthetising
  • A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
  • G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data

29.

IRON BASED MRI PROBES

      
Application Number US2023035599
Publication Number 2024/086331
Status In Force
Filing Date 2023-10-20
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Gale, Eric M.

Abstract

The present disclosure provides biochemically responsive Fe(II) and Fe(III) complexes useful as magnetic resonance imaging probes for diagnosis and monitoring acute and chronic inflammatory diseases affecting various organs and tissues.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • C07F 15/02 - Iron compounds
  • A61K 31/295 - Iron group metal compounds
  • A61K 33/26 - Iron; Compounds thereof

30.

IRON REPLACEMENT TREATMENTS

      
Application Number US2023076998
Publication Number 2024/086535
Status In Force
Filing Date 2023-10-16
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gale, Eric M.
  • Sargun, Artur
  • Babitt, Jodie
  • Fisher, Allison L.

Abstract

The present application provides compounds and methods for iron replacement therapy.

IPC Classes  ?

31.

ENGINEERED CASPHI2 NUCLEASES

      
Application Number US2023077523
Publication Number 2024/086845
Status In Force
Filing Date 2023-10-23
Publication Date 2024-04-25
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J. Keith
  • Grünewald, Julian
  • Miller, Bret
  • Holtz, Eliza, Jane

Abstract

Described herein are variants of CasPhi2 nucleases with enhanced editing capabilities and methods of use thereof.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

32.

LOCALIZATION AND TARGETING OF SMALL PULMONARY LESIONS

      
Application Number US2023076621
Publication Number 2024/081745
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • CANON U.S.A., INC. (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Beqari, Jorind
  • Hurd, Jacob
  • Masaki, Fumitaro
  • King, Franklin
  • Hata, Nobuhiko
  • Colson, Yolonda Lorig

Abstract

One or more devices, systems, methods, and storage mediums for performing robotic control and/or for performing localization and lesion targeting are provided herein. Examples of such control, localization and lesion targeting include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved and performing localization and lesion targeting in a bronchial pathway using a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for bronchial applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing, imaging, and lesion targeting efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.

IPC Classes  ?

  • A61B 34/32 - Surgical robots operating autonomously
  • A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
  • A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
  • A61B 34/30 - Surgical robots
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

33.

SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY

      
Application Number US2023076368
Publication Number 2024/081587
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-18
Owner
  • THE CHILDREN'S MEDICAL CENTER CORPORATION (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ozcan, Umut
  • Mazitschek, Ralph
  • Guan, Dongxian

Abstract

Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.

IPC Classes  ?

  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61P 3/04 - Anorexiants; Antiobesity agents

34.

IMAGING SLOW FLOW DYNAMICS OF CEREBROSPINAL FLUID USING MAGNETIC RESONANCE IMAGING

      
Application Number US2023076679
Publication Number 2024/081779
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dong, Zijing
  • Wang, Fuyixue
  • Wald, Lawrence, L.
  • Lewis, Laura
  • Polimeni, Jonathan

Abstract

Magnetic resonance imaging (MRI) is used to image the slow flow of cerebrospinal fluid (CSF) in subarachnoid and perivascular spaces, amongst other regions of the brain and central nervous system. The slow CSF flow imaging can be provided by using low velocity' encoding (VENC) and an efficient data acquisition. Tailored image processing can be used to further improve the accuracy, specificity, and visualization of CSF flow dynamics.

IPC Classes  ?

  • A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
  • A61B 5/0515 - Magnetic particle imaging
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • G01R 33/54 - Signal processing systems, e.g. using pulse sequences
  • G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
  • A61B 5/0522 - Magnetic induction tomography
  • A61B 5/0535 - Impedance plethysmography
  • G01R 33/48 - NMR imaging systems
  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

35.

SYSTEM AND METHOD FOR CONTROL OF IONIZING RADIATION DOSE IN MEDICAL APPLICATIONS USING SYNTHETIC LOCALIZERS

      
Application Number US2023076749
Publication Number 2024/081822
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yang, Kai
  • Sharma, Amita
  • Gupta, Rajiv
  • Marschall, Theodore
  • Savage, Cristy
  • Flynn, Karen
  • Redel, Travis
  • Mcnulty, Frederick

Abstract

Methods, system, and non-transitory media are provided for tube-current-modulation (TCM) calculation in computed tomography (CT) imaging. The radiation dose exposure is adjusted by identifying dose varying anatomical markers such as arms or removable objects that are not consistently positioned between localizer and actual scanning. Provided herein are means of reducing the effect of those anatomical markers on the TCM calculation by generating a synthetic localizer from an acquired localizer of a patient wherein the anatomical marker has been modified to match the actual scanning status. Modification of the dose-varying anatomical marker may include changing the position from an arms-down to arms up position or complete image signal removal of the arms or other markers from the localizer.

IPC Classes  ?

  • A61B 6/03 - Computerised tomographs
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • G06T 7/00 - Image analysis

36.

COMPOSITIONS AND METHODS USING REELIN IN ALZHEIMER'S DISEASE

      
Application Number US2023076914
Publication Number 2024/081934
Status In Force
Filing Date 2023-10-13
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • MASSACHUSETTS EYE AND EAR INFIRMARY (USA)
  • BANNER HEALTH (USA)
Inventor
  • Quiroz-Gaviria, Yakeel Tatiana
  • Arboleda-Velasquez, Joseph F.
  • Lopera, Francisco
  • Reiman, Eric

Abstract

Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C12N 15/86 - Viral vectors
  • C12N 9/22 - Ribonucleases
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

37.

ENGINEERED BIFUNCTIONAL RECEPTORS AND USES THEREOF

      
Application Number US2023076534
Publication Number 2024/081690
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Jan, Max
  • Ebert, Benjamin
  • Maus, Marcela
  • Manguso, Robert
  • Mears, Kepler
  • Lane, Isabel

Abstract

Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.

IPC Classes  ?

  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

38.

COVALENT COMPOUNDS AND USES THEREOF

      
Application Number US2023076610
Publication Number 2024/081739
Status In Force
Filing Date 2023-10-11
Publication Date 2024-04-18
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
Inventor
  • Iafrate, Anthony John
  • Bar-Peled, Liron
  • Yang, Diane
  • Liau, Brian
  • Harry, Stefan

Abstract

The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.

IPC Classes  ?

  • A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
  • A61K 31/03 - Halogenated hydrocarbons carbocyclic aromatic
  • A61K 31/035 - Halogenated hydrocarbons having aliphatic unsaturation
  • C07C 233/07 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

39.

METHOD AND SYSTEM FOR MOTION-ROBUST SUPER-RESOLUTION MAGNETIC RESONANCE IMAGING

      
Application Number US2023076639
Publication Number 2024/081753
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wang, Fuyixue
  • Dong, Zijing
  • Polimeni, Jonathan
  • Wald, Lawrence, L.

Abstract

The present disclosure provides a method for generating MRI images of a subject. The method includes accessing MRI images of the subject that have a first resolution, where each of the MRI images was acquired with a selected sampling pattern. The method further includes estimating motion between the MRI images to determine a motion transformation that corresponds to motion of the subject between the MRI images. The method further includes applying a model-based super-resolution reconstruction to the MRI images. The reconstruction accounts for the motion transformation and generates an image of the subject within the image volume that has a second resolution greater than the first resolution.

IPC Classes  ?

  • G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
  • G01R 33/385 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
  • G01R 33/566 -

40.

METHODS FOR ACCELERATED TIME-RESOLVED MULTI-ECHO MAGNETIC RESONANCE IMAGING BY AUGMENTING TEMPORAL CORRELATION

      
Application Number US2023076677
Publication Number 2024/081777
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wang, Fuyixue
  • Dong, Zijing
  • Polimeni, Jonathan
  • Wald, Lawrence, L.

Abstract

Accelerated time-resolved multi-echo magnetic resonance imaging (MRI) uses augmenting of the temporal correlation across echoes, for example, by applying gradient blips that sample the spatiotemporal space in a new trajectory to reduce dead time and echo spacing. Additionally or alternatively, acceleration may be achieved by optimization of the encoding pattern to reduce temporal distance and/or using a spatiotemporal partial Fourier acquisition.

IPC Classes  ?

  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
  • G16H 30/00 - ICT specially adapted for the handling or processing of medical images

41.

SYSTEM AND METHOD FOR MULTIPHOTON PARALLEL TRANSMIT EXCITATION FOR MRI

      
Application Number US2023076709
Publication Number 2024/081799
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wald, Lawrence, L.
  • Drago, John
  • Guerin, Bastien

Abstract

A method for generating a magnetic resonance image of a subject using a magnetic resonance imaging (MRI) system includes receiving, using the MRI system, at least one parameter for a multiphoton parallel transmit excitation comprising a multiphoton excitation pulse configured to correct spatial inhomogeneities and performing, using the MRI system, a pulse sequence comprising the multiphoton parallel transmit excitation to acquire data from the subject. The multi photon excitation pulse of the multi photon parallel transmit excitation is performed using a radio frequency (RF) coil and a set of one or more shim coils of the MRI system. The method further includes generating, using a processor, an image of the subject using the acquired MR data. In some embodiments, the multiphoton excitation pulse includes an off-resonance RF excitation pulse performed using the RF coil and a plurality of low-frequency excitation pulses performed using the set of one or more shim coils. The plurality of low-frequency excitation pulses are performed simultaneously with the off-resonance RF excitation pulse.

IPC Classes  ?

  • G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
  • G01R 33/3875 - Compensation of inhomogeneities using correction coil assemblies, e.g. active shimming
  • G01R 33/48 - NMR imaging systems
  • G01R 33/54 - Signal processing systems, e.g. using pulse sequences
  • G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
  • G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities

42.

LIBRARY-SCALE METHODS FOR POLYPEPTIDE FUNCTIONAL ANALYSIS

      
Application Number US2023076724
Publication Number 2024/081807
Status In Force
Filing Date 2023-10-12
Publication Date 2024-04-18
Owner
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Dekosky, Brandon
  • Jin, Shuyan
  • Johnson, Shelbe Marie
  • Gutierrez, Matias F.

Abstract

Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.

IPC Classes  ?

  • C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

43.

IMMUNOCAPTURE METHODS TO ENRICH FOR ENGINEERED EXTRACELLULAR VESICLES

      
Application Number US2023076828
Publication Number 2024/081876
Status In Force
Filing Date 2023-10-13
Publication Date 2024-04-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Breyne, Koen
  • Breakefield, Xandra O.

Abstract

Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.

IPC Classes  ?

  • A61K 9/127 - Liposomes
  • A61K 38/46 - Hydrolases (3)
  • A61K 38/53 - Ligases (6)
  • B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
  • C07K 19/00 - Hybrid peptides
  • C12N 9/22 - Ribonucleases
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

44.

MINIMALLY INVASIVE DEVICE FOR NERVE IDENTIFICATION, STIMULATION, AND MANIPULATION

      
Application Number US2023076364
Publication Number 2024/077294
Status In Force
Filing Date 2023-10-09
Publication Date 2024-04-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gfrerer, Lisa
  • Srinivasan, Shriya, S.
  • Austen, Jr., William, G.

Abstract

Systems and methods for an insertable medical device are described. The device comprises a device body configured to be insertable into a subject; proximal and distal openings; a cavity extending through the device body and in communication with the proximal opening and the distal opening, the cavity and the proximal opening being dimensioned to receive an instrument therein; a plurality of electrically conductive pads configured to be positioned a predetermined location relative to the proximal and distal openings, and configured to sense an electrical characteristic of the subject; an I/O device configured to: output signal data from the electrically conductive pads to a processing device operating a ML algorithm, the signal data including data corresponding to the electrical characteristic of the subject, and receive response data generated by the ML algorithm indicating a tissue type proximate respective electrically conductive pads based on an analysis of the signal data.

IPC Classes  ?

  • A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
  • A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

45.

SYSTEMS AND METHODS FOR RADIATION ONCOLOGY WORKFLOW MANAGEMENT

      
Application Number US2023076210
Publication Number 2024/077222
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Wolfgang, John

Abstract

A radiation oncology workflow management system is provided. The system may include interactive graphical interface and a particularly programmed processor, thereby to perform operations including displaying a window containing a user interface (UI) environment on a computer screen, parsing an input received from a user via the UI environment, thereby to determine which of a plurality of atomic application functions is indicated by the input, automatically interacting with an atomic application associated with the atomic application function determined to be indicated by the input, and automatically displaying information received from the atomic application via the UI environment.

IPC Classes  ?

  • G06Q 10/10 - Office automation; Time management
  • G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
  • G06Q 10/0633 - Workflow analysis
  • G06Q 50/22 - Social work
  • G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
  • G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
  • G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

46.

METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OF PEPTIDE-MHC TARGETING BINDING PROTEINS

      
Application Number US2023076267
Publication Number 2024/077256
Status In Force
Filing Date 2023-10-06
Publication Date 2024-04-11
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Hacohen, Nir
  • Liu, Bingxu
  • Bakalar, Matthew
  • Chen, Xun

Abstract

The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.

IPC Classes  ?

  • C07K 14/725 - T-cell receptors
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

47.

ARTIFICIAL INTELLIGENCE ENABLED DISCRIMINATION OF DISEASE AND DISEASE ETIOLOGY

      
Application Number US2023033803
Publication Number 2024/072849
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Lubitz, Steven
  • Batra, Puneet
  • Haimovich, Julian
  • Diamant, Nathaniel
  • Khurshid, Shaan
  • Ho, Jennifer

Abstract

The subject matter disclosed herein relates using waveform data of a subject to detect one or more diseases or disease etiologies. Particular examples relate to providing a system, a computer-implemented method, and a computer program product to waveform data to detect and differentiate particular diseases and disease etiologies with machine learning models.

IPC Classes  ?

  • A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/341 - Vectorcardiography [VCG]
  • A61B 5/346 - Analysis of electrocardiograms
  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
  • G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

48.

MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (OHSV) AND METHODS OF USE THEREOF

      
Application Number US2023075127
Publication Number 2024/073416
Status In Force
Filing Date 2023-09-26
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Martuza, Robert L.
  • Rabkin, Samuel D.
  • Saha, Dipongkor
  • Jahan, Nusrat

Abstract

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C12N 15/86 - Viral vectors
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/869 - Herpesviral vectors
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome
  • C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

49.

ADMINISTRATION OF GLUTATHIONE TRISULFIDE TO AMELIORATE PERIPHERAL NEUROPATHY

      
Application Number US2023075131
Publication Number 2024/073420
Status In Force
Filing Date 2023-09-26
Publication Date 2024-04-04
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • KYOWA HAKKO BIO CO., LTD. (Japan)
Inventor
  • Ichinose, Fumito
  • Ezaka, Mariko
  • Ohshima, Etsuo

Abstract

Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.

IPC Classes  ?

  • A61K 38/06 - Tripeptides
  • C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
  • A61K 31/095 - Sulfur, selenium or tellurium compounds, e.g. thiols
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

50.

4-1BBL AND IL-12 THERAPY FOR TREATMENT OF GLIOBLASTOMA

      
Application Number US2023075225
Publication Number 2024/073483
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Breyne, Koen
  • Breakefield, Xandra O.
  • Mempel, Thorsten R.

Abstract

Provided herein are methods of treating glioblastoma including administering to a subject having glioblastoma a therapeutically effective amount of a pharmaceutical composition comprising 4-1BBL, optionally in combination with recombinant IL-12. The 4-1BBL can be provided to the subject via an adeno-associated virus, for example AAV-F, and the IL-12 can be provided by intratumoral injection.

IPC Classes  ?

  • A61K 38/20 - Interleukins
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

51.

PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION

      
Application Number US2023075230
Publication Number 2024/073486
Status In Force
Filing Date 2023-09-27
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wu, Xu
  • Hu, Lu

Abstract

The present disclosure relates to compounds of Formula I and methods comprising the use of these compounds to identify ligandable fatty acylation sites.

IPC Classes  ?

  • G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
  • G01N 33/483 - Physical analysis of biological material
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

52.

SYSTEM AND METHOD FOR DETERMINING PERFUSED TISSUE VIABILITY

      
Application Number US2023075328
Publication Number 2024/073540
Status In Force
Filing Date 2023-09-28
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Evans, Conor, L.
  • Berkane, Yanis
  • Uygun, Mustafa, Korkut
  • Cascales Sandoval, Juan
  • Lellouch, Alexandre, G.
  • Rousakis, Emmanouil

Abstract

The disclosure provides perfusion systems and methods for continuous or intermittent perfusion to monitor and extend the viability of tissue for transplants. Intermittent perfusion involves generating perfusion cycles which alternate between baseline and high oxygen gas partial pressure in the circulating perfusate. The system comprises a perfusion fluid source and an inflow conduit in fluid communication with the perfusion fluid source and a tissue sample, wherein the inflow conduit is configured to deliver perfusion fluid to the tissue sample. The system further comprises an outflow conduit in fluid communication with the tissue sample, wherein the outflow conduit is configured to carry perfusion fluid away from the tissue sample. A first gas sensor is in fluid communication with the inflow-conduit and measures a. concentration of a gas in perfusion fluid, in the inflow conduit, and a second gas sensor is in contact with the tissue sample and measures a concentration of a gas in the sample.

IPC Classes  ?

53.

GENE THERAPY FOR GENETIC AND ACQUIRED VASCULOPATHIES

      
Application Number US2023075589
Publication Number 2024/073715
Status In Force
Filing Date 2023-09-29
Publication Date 2024-04-04
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Musolino, Patricia L.
  • Lindsay, Mark Evan
  • Kleinstiver, Benjamin P
  • Maguire, Casey A.
  • Chung, David Young
  • Cardenas, Christian Lacks Lino
  • Malhotra, Rajeev

Abstract

Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant alleles or a Cas nuclease that knocks out the mutant allele.

IPC Classes  ?

54.

METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

      
Application Number US2023074708
Publication Number 2024/064766
Status In Force
Filing Date 2023-09-20
Publication Date 2024-03-28
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
Inventor
  • Letai, Anthony
  • Knisbacher, Binyamin
  • Parvin, Salma
  • Getz, Gad
  • Wu, Catherine

Abstract

As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.

IPC Classes  ?

  • G01N 33/483 - Physical analysis of biological material
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

55.

AN ENZYMATIC SYSTEM FOR PRECISE CELL TARGETING

      
Application Number US2023074780
Publication Number 2024/064818
Status In Force
Filing Date 2023-09-21
Publication Date 2024-03-28
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Holden, Rebecca
  • Bakalar, Matt
  • Hacohen, Nir

Abstract

The disclosure provides compositions and methods for enzyme-mediated precise cell targeting.

IPC Classes  ?

  • C12N 9/88 - Lyases (4.)
  • C12Q 1/527 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

56.

MICROMOTOR AND OPTICAL ARRANGEMENT FOR FAST CIRCULAR SCANNING OF LIGHT BEAMS IN SMALL DIAMETER FLEXIBLE CATHETERS

      
Application Number US2023074596
Publication Number 2024/064689
Status In Force
Filing Date 2023-09-19
Publication Date 2024-03-28
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Bouma, Brett, E.
  • Shishkov, Milen
  • Uribe-Patarroyo, Néstor
  • Schmidt, Ginger

Abstract

The disclosure presents a shaftless, brushless motor for rotating any optical or sensing element (e.g., a lens or mirror) at a distal end of a waveguide that also delivers electromagnetic radiation (e.g., light). Herein, the waveguide itself functions as the axle on which rotating components rotate, thereby avoiding blind spots and overcoming limitations in existing "micromotors". The shaftless, distally driven motor significantly reduces motor size, while extremely small inertial loads and bearing sizes allow for high pitch cylindrical scanning with longitudinal velocity uniformity.

IPC Classes  ?

  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • G02B 6/00 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings

57.

METHOD AND APPARATUS FOR MODULATING SIGNALS OF LUMINESCENT POLYMER/DYE FORMULATIONS USING LIGHT SCATTERING PARTICLES

      
Application Number US2023074688
Publication Number 2024/064750
Status In Force
Filing Date 2023-09-20
Publication Date 2024-03-28
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • 3M INNOVATIVE PROPERTIES COMPANY (USA)
Inventor
  • Müller, Matthias
  • Evans, Conor, L.
  • Rousakis, Emmanouil
  • Cascales Sandoval, Juan, Pedro
  • Bjork, Jason
  • Muyres, Dawn
  • Wilken-Resman, Elias
  • Demirgöz, Döne
  • Apiou, Gabriela

Abstract

A sensing system and method for sensing an analyte. The sensing system includes; a sensing material having one or more layers, the sensing material including; a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix. The sensing method includes: providing a sensing material including one or more layers, the sensing material including a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix, the light emitting material being sensitive to an analyte; exposing the sensing system to the analyte; and measuring a change in a light emission from the light emitting material based on exposing the sensing system to the analyte.

IPC Classes  ?

  • A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
  • G01N 21/64 - Fluorescence; Phosphorescence
  • A61F 13/00 - Bandages or dressings; Absorbent pads

58.

SUPRAMOLECULAR HYBRID HYDROGELS FOR BURN AND WOUND DRESSINGS

      
Application Number US2023032178
Publication Number 2024/054562
Status In Force
Filing Date 2023-09-07
Publication Date 2024-03-14
Owner
  • TRUSTEES OF TUFTS COLLEGE (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Asatekin Alexiou, Ayse
  • Gokaltun, Ayse, Aslihan
  • Usta, Osman, Berk
  • Mazzaferro, Luca
  • Stafford, Zosia

Abstract

Disclosed are supramolecular hybrid hydrogels (SHH), wound dressings, comprising supramolecular hybrid hydrogels; and methods of treating wounds, including burns.

IPC Classes  ?

  • A61F 13/00 - Bandages or dressings; Absorbent pads
  • A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
  • A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages

59.

RETT SYNDROME THERAPY

      
Application Number GB2023052315
Publication Number 2024/052681
Status In Force
Filing Date 2023-09-07
Publication Date 2024-03-14
Owner
  • THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (United Kingdom)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kleinstiver, Benjamin
  • Guy, Jacqueline
  • Bird, Adrian

Abstract

The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wild¬ type version of the MeCP2 protein.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 9/22 - Ribonucleases
  • C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

60.

SYSTEMS AND METHODS FOR ATTENUATING ACOUSTIC WAVES

      
Application Number US2023073768
Publication Number 2024/054990
Status In Force
Filing Date 2023-09-08
Publication Date 2024-03-14
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yun, Seok-Hyun
  • Shabahang, Soroush

Abstract

An acoustic filter can include a first substrate including a first plurality of holes directed, therethrough, a second substrate including a second plurality of holes directed therethrough, a chamber defined between the first substrate and the second substrate, and a membrane positioned within the chamber. The membrane can have a dimension other than the thickness of the membrane that can be less than a corresponding dimension of the chamber. The acoustic filter can be configured to attenuate a first acoustic wave that passes through the acoustic filter, the first acoustic wave can have a first amplitude above an amplitude threshold. The acoustic filter can be configured to passthrough a second acoustic wave without substantially attenuating the second acoustic wave, the second acoustic wave can have a second amplitude below' the amplitude threshold.

IPC Classes  ?

  • G10K 11/04 - Acoustic filters
  • A61F 11/08 - Protective devices for the ears internal, e.g. earplugs

61.

PERFUSABLE 3D TUBULE-ON-CHIP MODEL DERIVED FROM KIDNEY ORGANOIDS WITH IMPROVED DRUG UPTAKE

      
Application Number US2023073271
Publication Number 2024/050497
Status In Force
Filing Date 2023-09-01
Publication Date 2024-03-07
Owner
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Aceves, Jeffrey, O.
  • Wolf, Kayla
  • Robinson, Sanlin, S.
  • Morizane, Ryuji
  • Lewis, Jennifer
  • Van Gaal, Ronald

Abstract

Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.

IPC Classes  ?

  • A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
  • A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland

62.

HIGH-RESOLUTION AND NON-INVASIVE FETAL SEQUENCING

      
Application Number US2023031556
Publication Number 2024/049915
Status In Force
Filing Date 2023-08-30
Publication Date 2024-03-07
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Talkowski, Michael E
  • Brand, Harrison

Abstract

Provided herein are computer-implemented methods for assigning maternal or fetal origin to one or more genetic variants in cell free DNA (cfDNA) from a sample from a pregnant mammal, preferably a pregnant human, using a probabilistic model for assigning maternal or fetal origin to genetic variants in DNA from a sample obtained from a pregnant mammal, wherein the model assigns maternal or fetal origin based on a combination of fetal fraction and DNA fragment size.

IPC Classes  ?

  • G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
  • C12Q 1/6869 - Methods for sequencing
  • G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
  • G16B 20/10 - Ploidy or copy number detection
  • G16B 30/10 - Sequence alignment; Homology search
  • C12Q 1/6804 - Nucleic acid analysis using immunogens
  • G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
  • G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

63.

COMPOSITIONS AND METHODS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS

      
Application Number US2023072851
Publication Number 2024/044708
Status In Force
Filing Date 2023-08-24
Publication Date 2024-02-29
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Pinto, Ricardo, Mouro
  • Kleinstiver, Benjamin

Abstract

Methods and compositions for reducing expansion of nucleotide repeats in a cell, comprising base editors and a guide RNA (gRNA) that directs the Cas-based enzyme to the splice acceptor site for mutL homolog 3 (MLH3) exon 7 or to the MLH3 endonuclease domain.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

64.

METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF DILATED CARDIOMYOPATHY AND HEART FAILURE

      
Application Number US2023031136
Publication Number 2024/044352
Status In Force
Filing Date 2023-08-25
Publication Date 2024-02-29
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
  • THE BROAD INSTITUTE, INC. (USA)
Inventor
  • Aragam, Krishna
  • Huffman, Jennifer
  • Gaziano, Liam

Abstract

CD36CD36CD36 mutation in a sample from the subject.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

65.

INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS

      
Application Number US2023030074
Publication Number 2024/039584
Status In Force
Filing Date 2023-08-11
Publication Date 2024-02-22
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Choi, Hak Soo
  • Kang, Homan

Abstract

Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.

IPC Classes  ?

66.

ENDOVASCULAR BIOLOGIC STENT

      
Application Number US2023071910
Publication Number 2024/036199
Status In Force
Filing Date 2023-08-09
Publication Date 2024-02-15
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Singh, Varun
  • Gaston, Brandon

Abstract

Disclosed herein are implantable vascular devices and methods of use thereof. Exemplary embodiments of the implantable vascular device comprise a tubular stent component, and one or more of a cell compartment, a graft component, or a bioscaffold, along with one or more support members providing a fixed position between the tubular stent component and the cell compartment, graft component, or bioscaffold. Preferably, the one or more support members provide a collapsible fixed position. Methods of use include methods of implanting and methods of removing, the device, as well as methods of reseeding the device, in some embodiments.

IPC Classes  ?

  • A61F 2/07 - Stent-grafts
  • A61F 2/86 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure
  • A61L 31/00 - Materials for other surgical articles

67.

MATERIALS AND METHODS FOR LUMINESCENCE-BASED CARBON DIOXIDE SENSING

      
Application Number US2023065836
Publication Number 2024/030687
Status In Force
Filing Date 2023-04-17
Publication Date 2024-02-08
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Li, Xiaolei
  • Cascales Sandoval, Juan, Pedro
  • Rousakis, Emmanouil
  • Evans, Conor, L.

Abstract

A device for carbon dioxide monitoring is disclosed. The device comprises: a photoluminescent carbon dioxide-sensitive probe comprising a polymer matrix and a sensing dye; a photon source configured to direct photons at the probe; a photodetector configured to detect light emitted from the probe when the photon source directs photons at the probe; a carbon dioxide permeable light redirection layer, wherein the carbon dioxide-sensitive probe is positioned between the light redirection layer and the photodetector; and a controller in electrical communication with the photon source and the photodetector, the controller being configured to execute a program stored in the controller to calculate a level of carbon dioxide adjacent the probe from an electrical signal received from the photodetector. In one form, the polymer matrix comprises a polymer selected from the group consisting of acrylate polymers, methacrylate polymers, polyurethane polymers, and blends and copolymers thereof.

IPC Classes  ?

  • G01N 21/64 - Fluorescence; Phosphorescence
  • A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
  • G01J 1/58 - Photometry, e.g. photographic exposure meter using luminescence generated by light
  • G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroups; Apparatus specially adapted for such methods using chemical indicators
  • C08L 75/04 - Polyurethanes
  • C08F 20/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
  • A61B 5/1495 - Calibrating or testing in vivo probes

68.

RETROGRADE TETHERED CAPSULE ENDOMICROSCOPY SYSTEMS AND METHODS

      
Application Number US2023071600
Publication Number 2024/031010
Status In Force
Filing Date 2023-08-03
Publication Date 2024-02-08
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Tearney, Guillermo
  • Tinus, Makayla
  • Sevieri, Evan
  • Lai, Weixuan
  • Song, Du-Ri
  • Hou, Fang
  • Pitris, Constaninos
  • Thrapp, Andrew

Abstract

A system for performing retrograde tethered capsule endomicroscopy, including: a capsule including at least one outwardly-facing helical thread; a drive shaft coupled to the capsule and configured to rotate the capsule; and an optical system disposed within the capsule and configured to obtain circumferential imaging information. A method for performing retrograde tethered capsule endomicroscopy, comprising: providing a capsule comprising at least one outwardly-facing helical thread and an optical system disposed within the capsule; rotating the capsule using a drive shaft coupled to the capsule; and obtaining circumferential imaging information using the optical system disposed within the capsule.

IPC Classes  ?

  • A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
  • A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
  • A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

69.

BIOSENSOR CARTRIDGE AND BIOSENSOR DEVICE COMPRISING SAME

      
Application Number KR2023010942
Publication Number 2024/025365
Status In Force
Filing Date 2023-07-27
Publication Date 2024-02-01
Owner
  • ELIPS DIAGNOSTICS INC. (Republic of Korea)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Shin, Ik-Soo

Abstract

A biosensor cartridge is disclosed. The biosensor cartridge, which detects biological material so as to generate an electrochemiluminescence signal, according to one aspect of the present invention, comprises: an electrode unit including a plurality of electrodes; and a dividing unit disposed on the electrode unit so as to divide the entire space provided on the electrode unit into a signal chamber and N-number of reaction chambers, which encompass the signal chamber, wherein the electrode unit includes a first electrode of which at least a portion is disposed in the reaction chambers, a second electrode disposed in the signal chamber, and N-number of connection electrodes disposed to electrically link the chemical reaction in the reaction chambers and the electrochemiluminescence signal generated in the signal chamber.

IPC Classes  ?

  • G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
  • G01N 21/76 - Chemiluminescence; Bioluminescence
  • G01N 27/327 - Biochemical electrodes
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

70.

HIGH-THROUGHPUT PROTEOME MAPPING

      
Application Number US2023029015
Publication Number 2024/026114
Status In Force
Filing Date 2023-07-28
Publication Date 2024-02-01
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Haas, Wilhelm
  • Hajizadeh, Soroush

Abstract

Methods, systems, and apparatus, including computer programs encoded on computer storage media, for proteome mapping. One of the methods includes: identifying one or more target peptide sequences for a sample; estimating an elution order of one or more expected peptides from a chromatography column; and initiating generation of a first set of mass spectrometry spectra for the sample. The method also includes detecting peaks within the first set of mass spectrometry spectra to determine a real-time status with respect to the estimated elution order; selecting one or more peptide ions that are (i) observed in the first set of mass spectrometry spectra and (ii) included among the one or more peptides expected to be present in the sample; and initiating generation of a second set of mass spectrometry spectra for the one or more selected peptide ions.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
  • G01N 30/86 - Signal analysis
  • G01N 33/72 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. hemoglobin, bilirubin
  • G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
  • G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

71.

CCCTC-BINDING FACTOR (CTCF)-MEDIATED GENE ACTIVATION

      
Application Number US2023070852
Publication Number 2024/026269
Status In Force
Filing Date 2023-07-24
Publication Date 2024-02-01
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Joung, J., Keith
  • Tak, Yugyoung, Esther
  • Cottman, Rebecca, Tayler

Abstract

Methods for increasing expression of a target gene, the method comprising introducing a CCCTC-binding factor (CTCF) binding site (CTCF-BS) into a promoter region of the target gene, e.g., within 500, 250, 200, 150, 100, 50, or 25 nucleotides of the transcription start site (TSS) for the target gene, and optionally expressing in or introducing into the cell a CTCF protein or variant thereof.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C12N 9/22 - Ribonucleases
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
  • C12N 15/12 - Genes encoding animal proteins

72.

METHODS AND SYSTEMS OF ENHANCING ELECTROMAGNETIC RADIATION SIGNALS FROM EXTRACELLULAR VESICLES

      
Application Number US2023070948
Publication Number 2024/026314
Status In Force
Filing Date 2023-07-25
Publication Date 2024-02-01
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Im, Hyungsoon
  • Weissleder, Ralph

Abstract

Systems, methods, and devices are described herein for use in detecting and/or monitoring target extracellular vesicles ("EVs"), e.g., to detect and/or monitor treatment for a disease, e.g., for cancer, in a subject. The systems can include nano-plasmonic arrays of nanostructures arranged to form a periodic array on a substrate, and each nanostructure can include a nanopillar, a spacer layer, e.g., coated onto a metallic layer, and a plurality of metal nanoparticles bound to each of the nanopillars. The nano-plasmonic arrays amplify specific wavelengths of electromagnetic radiation and can be used to capture and image target EVs.

IPC Classes  ?

  • G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
  • G01N 15/02 - Investigating particle size or size distribution
  • G01N 15/14 - Electro-optical investigation
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N 21/552 - Attenuated total reflection
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N 21/65 - Raman scattering

73.

METHODS AND COMPOSITIONS FOR USE IN TREATING AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD)

      
Application Number US2023071029
Publication Number 2024/026354
Status In Force
Filing Date 2023-07-26
Publication Date 2024-02-01
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Hiratsuka, Ken
  • Morizane, Ryuji

Abstract

Provided herein are compositions and methods of use thereof for treating Autosomal recessive polycystic kidney disease (ARPKD) by targeting Rac family small GTPase 1 (RAC1 ) and/or Fos proto-oncogene, AP-1 transcription factor subunit (FOS) by administering a therapeutically effective amount of an inhibitor of RAC1 and/or FOS to a subject in need thereof.

IPC Classes  ?

  • A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

74.

HLA-II IMMUNOPEPTIDOME METHODS AND SYSTEMS FOR ANTIGEN DISCOVERY

      
Application Number US2023070102
Publication Number 2024/015892
Status In Force
Filing Date 2023-07-13
Publication Date 2024-01-18
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Xavier, Ramnik
  • Graham, Daniel
  • Strazar, Martin

Abstract

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-CoV-2.

IPC Classes  ?

75.

ASSAY FOR MEASUREMENT OF PROPTH IN THE CIRCULATION

      
Application Number US2023027288
Publication Number 2024/015310
Status In Force
Filing Date 2023-07-10
Publication Date 2024-01-18
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Jueppner, Harald, W.

Abstract

The invention features a composition including (i) pro-parathyroid hormone (pro-PTH); and (ii) an antibody that specifically binds to pro-PTH.

IPC Classes  ?

  • C07K 14/635 - Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
  • C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
  • G01N 33/74 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones

76.

SYSTEMS FOR ELECTROENCEPHALOGRAPHY AND METHODS FOR USE AND MANUFACTURE OF THE SAME

      
Application Number US2023069706
Publication Number 2024/011174
Status In Force
Filing Date 2023-07-06
Publication Date 2024-01-11
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Bonmassar, Giorgio

Abstract

Systems and methods are provided for forming a system for transmitting electrical signals to or from the head of a subject. The system includes a base layer. A layer of conductive, non-ferrous material may be deposited along an upper surface of the base layer using a thin-film deposition technique, which is patterned into a conductive trace that extends between a proximal end and a distal end of the base layer. A thick film forming an electrode is positioned relative to a distal end of the conductive trace.

IPC Classes  ?

77.

SYSTEMS AND METHODS FOR PREPARING A TRANSPLANT SITE FOR RECEIVING FOLLICULAR TRANSPLANTS AND FOR EFFECTUATING FOLLICULAR TRANSPLANTS

      
Application Number US2023068930
Publication Number 2023/250452
Status In Force
Filing Date 2023-06-23
Publication Date 2023-12-28
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Austen, Jr., William Gerald

Abstract

An apparatus and method for removing dermal tissue from a dermis layer. The apparatus can include a hollow needle with a proximal end, a distal end, and a central lumen extending from the proximal end through the distal end. Properties of the hollow needle can be selected such that the hollow needle can be inserted into dermal tissue to remove a portion of tissue from a transplant site in preparation for the insertion of a hair follicle from a donor site. Some apparatus can include a plurality of hollow needles and/or a reciprocating arrangement to mechanically advance and withdraw the one or more hollow needles.

IPC Classes  ?

78.

BICYCLONONYNE REAGENTS FOR CELL IMAGING

      
Application Number US2023068279
Publication Number 2023/244963
Status In Force
Filing Date 2023-06-12
Publication Date 2023-12-21
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Weissleder, Ralph
  • Carlson, Jonathan C.

Abstract

The present disclosure provides bicyclononyne based compounds and methods to prepare an antibody conjugate with a fluorophore, as well as the methods of using these conjugates for cellular imaging. In one example, the conjugate may be coupled with a quencher to absorb fluorescence from the fluorophore.

IPC Classes  ?

  • C07K 1/13 - Labelling of peptides
  • C07C 13/45 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing nine carbon atoms
  • C07C 211/19 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing condensed ring systems
  • C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

79.

COMPOSITIONS AND METHODS FOR CONTROL OF TRANSIENT SITE-SPECIFIC COPY GAINS, GENOMIC INSERTIONS, AND REARRANGEMENTS ASSOCIATED WITH MIXED LINEAGE LEUKEMIA

      
Application Number US2023025793
Publication Number 2023/244870
Status In Force
Filing Date 2023-06-20
Publication Date 2023-12-21
Owner
  • INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Whetstine, Johnathan, R.
  • Gray, Zach, H.
  • Chakraborty, Damayanti
  • Duttweiler, Reuben, R.
  • Murphy, Sedona, E.
  • Alekbaeva, Gulnaz

Abstract

Compositions and methods for control of transient site-specific copy gains and genomic insertion associated with mixed lineage leukemia are provided.

IPC Classes  ?

  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61K 38/46 - Hydrolases (3)
  • A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

80.

SYSTEM FOR AND METHOD OF MEASURING BLOOD PRESSURE NON-INVASIVELY WITH LIGHT

      
Application Number US2023068553
Publication Number 2023/245149
Status In Force
Filing Date 2023-06-15
Publication Date 2023-12-21
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Franceschini, Maria, A.
  • Renna, Marco
  • Robinson, Mitchell
  • Wu, Kuan

Abstract

Optical patient monitoring systems are disclosed. The system may comprise an optical coupling system configured to transmit to and receive light signals from one or more locations on a subject; an optical processing system configured to generate optical data using the received light signals; and a computer programmed to receive the optical data; determine, using the optical data, at least one indicator of blood pressure; estimate an estimated blood pressure using the at least one indicator of blood pressure; and generate a report indicative of the estimated blood pressure. The at least one indicator of blood pressure comprises one or more of near-infrared spectroscopy (NIRS) data; photoplethysmography (PPG) data, diffuse correlation spectroscopy (DCS) data, speckle contrast optical spectroscopy (SCOS) data, speckleplethysmography (SPG) data, first derivative PPG data, second derivative PPG data, first derivative SPG data, second derivative SPG data, inflow (Fin) data, outflow (Fout) data, heart rate data, physiological data, and combinations thereof. Methods for estimating blood pressure are also disclosed.

IPC Classes  ?

  • A61B 5/021 - Measuring pressure in heart or blood vessels
  • A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
  • A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
  • A61B 5/369 - Electroencephalography [EEG]

81.

PREVENTING IMMUNOTHERAPY-INDUCED EDEMA USING ANGIOTENSIN RECEPTOR BLOCKERS

      
Application Number US2023024963
Publication Number 2023/239924
Status In Force
Filing Date 2023-06-09
Publication Date 2023-12-14
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Jain, Rakesh, K.
  • Datta, Meenal
  • Suva, Mario
  • Xu, Lei

Abstract

The disclosure features methods and compositions for the prevention of immunotherapy induced edema in glioblastoma patients undergoing immunotherapy.

IPC Classes  ?

  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 31/4164 - 1,3-Diazoles
  • A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
  • A61K 31/33 - Heterocyclic compounds

82.

SYSTEM, METHOD, AND APPARATUS FOR MICRONEEDLE ARRAY-BASED IMMUNOSENSORS FOR MULTIPLEX DETECTION OF BIOMARKERS

      
Application Number US2023066737
Publication Number 2023/239990
Status In Force
Filing Date 2023-05-08
Publication Date 2023-12-14
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Wu, Meixiong
  • Lin, Zuan-Tao

Abstract

A system for identifying a plurality of biomarkers in a sample, including: a substrate including a plurality of microneedles projecting therefrom, each of the plurality of microneedles including a plurality of biomarker recognition molecules attached thereto, and the plurality of microneedles including a first microneedle and a second microneedle, the first microneedle including a first plurality of biomarker recognition molecules configured to recognize a first biomarker, and the second microneedle including a second plurality of biomarker recognition molecules configured to recognize a second biomarker different from the first biomarker.

IPC Classes  ?

  • A61B 5/15 - Devices for taking samples of blood

83.

SYSTEMS AND METHODS FOR TREATING EYELID INFLAMMATION

      
Application Number US2023068096
Publication Number 2023/240161
Status In Force
Filing Date 2023-06-07
Publication Date 2023-12-14
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Anderson, Richard, R.
  • Dai, Tianhong
  • Levin, Yakir

Abstract

An eyelid treatment system can include a contact lens that can include an inner concave surface and an outer convex surface opposite the inner concave surface. The contact lens can be configured to be placed on an eyeball of a subject. The eyelid treatment system can include a light source optically coupled to the contact lens. The light source can be configured to deliver light to an inner surface of an eyelid of the subject when the contact lens is placed on the eyeball. The inner concave surface can be configured to at least partially block light from being transmitted through the inner concave surface, such that the light propagates in a direction away from the eyeball of the subject. The light from the light source can be configured to reduce eyelid inflammation.

IPC Classes  ?

84.

METHODS AND COMPOSITIONS FOR DETERMINING THE ANTIGEN SPECIFICITY OF T CELLS

      
Application Number US2023067706
Publication Number 2023/235761
Status In Force
Filing Date 2023-05-31
Publication Date 2023-12-07
Owner
  • THE BROAD INSTITUTE, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Hacohen, Nir
  • Bakalar, Matthew

Abstract

E. coliE. coli cells that encapsulate an RNA barcode encoding the peptide identity.

IPC Classes  ?

  • C07K 14/74 - Major histocompatibility complex (MHC)
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 9/90 - Isomerases (5.)
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • C12N 15/70 - Vectors or expression systems specially adapted for E. coli

85.

METHODS OF EARLY IDENTIFICATION AND EARLY INTERVENTION FOR HIGH-RISK NEONATES WHO OTHERWISE WILL DEVELOP AUTISTIC SOCIAL IMPAIRMENTS LATER IN LIFE

      
Application Number US2023067863
Publication Number 2023/235864
Status In Force
Filing Date 2023-06-02
Publication Date 2023-12-07
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Kong, Xue-Jun
  • Dong, Cun-Jian

Abstract

Limosilactobacillusreuteri L. reuteriL. reuteri L. reuteri in a sample from the subject.

IPC Classes  ?

  • C12Q 1/6851 - Quantitative amplification
  • A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • C12Q 1/686 - Polymerase chain reaction [PCR]
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
  • A61P 25/00 - Drugs for disorders of the nervous system

86.

ANTI-BMP9 ANTIBODIES AND METHODS OF USE THEREOF

      
Application Number IB2023055592
Publication Number 2023/233330
Status In Force
Filing Date 2023-05-31
Publication Date 2023-12-07
Owner
  • PFIZER INC. (USA)
  • THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yu, Paul B.
  • Apgar, James Reasoner
  • Benard, Susan Adam
  • Berasi, Stephen Peter
  • Huard, Christine
  • Kovalenko, Oleg Victorovich
  • Mosyak, Lidia
  • Tang, Xianchun
  • Tumelty, Kathleen Elisabeth
  • Troncone, Luca
  • Zhong, Ying

Abstract

Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

IPC Classes  ?

  • C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
  • A61P 11/00 - Drugs for disorders of the respiratory system
  • A61P 9/00 - Drugs for disorders of the cardiovascular system

87.

SYSTEMS, COMPOSITIONS, AND METHODS RELATING TO NEURODEGENERATIVE DISEASES

      
Application Number US2023067872
Publication Number 2023/235871
Status In Force
Filing Date 2023-06-02
Publication Date 2023-12-07
Owner
  • SEER, INC. (USA)
  • THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Zamanighomi, Mahdi
  • Guturu, Harendra
  • Wang, Jian
  • Huang, Ting
  • Siddiqui, Asim
  • Batzoglou, Serafim
  • Venkataraman, Guhan
  • Arnold, Steven E.
  • Webb, Pia Kivisakk
  • Das, Sudeshna
  • Hyman, Bradley Theodore

Abstract

In some aspects, the present disclosure provides a method for determining a risk or state of a neurodegenerative disease of a subject. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: E7EUF1, O94812, P02549, P02730, P05019, P05154, P05546, P13497, P16157, P16452, P17936, P24593, P27918, P35858, P41218, Q12797, Q13214, Q13822, Q8NI99, Q96IY4, Q99715, Q9BXN1, Q9H0B8, or a proteoform thereof. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: P54803, P14625, P30043, P00742, A0A0D9SG88, Q5TFM2, P54803, P54803-3, P54803-4, P04196, or a proteoform thereof. In some embodiments, the method comprises determining the risk or state of the neurodegenerative disease of the subject based on the presence of the biomarker in the biological sample.

IPC Classes  ?

  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

88.

METHODS OF IDENTIFYING GENETICALLY-ANCHORED MOLECULAR SIGNATURES FOR DISEASE AND TREATMENTS THEREOF

      
Application Number US2023067527
Publication Number 2023/230592
Status In Force
Filing Date 2023-05-26
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Claussnitzer, Melina
  • Udler-Aubrey, Miriam

Abstract

The present invention provides a method for obtaining genetically-anchored molecular signatures that are molecular signatures linked to genetic risk variants and that define mechanistic disease pathways in order to facilitate improved disease sub-classification, develop of novel rational therapeutics, and implement targeted prevention practices. The signatures can be obtained using polygenic risk scores and gene expression data, such as partitioned polygenic risk scores. In certain embodiments, the method further comprises identifying one or more key regulatory features of the genetically-anchored molecular signature by matching the genetically-anchored molecular signature with one or more perturbation molecular signatures from a perturbation data set using similarity scoring

IPC Classes  ?

  • C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
  • C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

89.

COMBINATION TREATMENT FOR ADENOCARCINOMA

      
Application Number US2023023492
Publication Number 2023/230212
Status In Force
Filing Date 2023-05-25
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ting, David T.
  • You, Eunae
  • Ebright, Richard Y
  • Desai, Niyati

Abstract

Described herein are methods for treating a carcinoma in a subject, the method comprising administering to the subject a therapeutically effective amount of (5z)-7-oxozeaenol (Oxo) or an analog thereof, optionally in combination with chemotherapy.

IPC Classes  ?

  • A61K 31/365 - Lactones
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61P 35/00 - Antineoplastic agents
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

90.

MODULATION OF BACE1 AS A THERAPY FOR SPINOCEREBELLAR ATAXIA

      
Application Number US2023023613
Publication Number 2023/230282
Status In Force
Filing Date 2023-05-25
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Suh, Jaehong

Abstract

Described herein are methods and compositions for treating neurodegenerative diseases including Spinocerebellar Ataxia comprising administering a BACE1 inhibitor.

IPC Classes  ?

  • A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • A61P 27/00 - Drugs for disorders of the senses

91.

SYSTEM FOR STABILIZED NONINVASIVE IMAGING OF MICROVASCULATURE IN THE ORAL MUCOSA

      
Application Number US2023067342
Publication Number 2023/230463
Status In Force
Filing Date 2023-05-23
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Bagramyan, Arutyun
  • Lin, Charles
  • Wu, Juwell, W.

Abstract

Disclosed is a system for imaging of microvasculature of tissue of a subject. The system can comprise: (a) a tissue stabilizer structured to contact the tissue of the subject to maintain a position of the region of microvasculature being imaged, and (b) an imaging instrument including: (i) a housing having an imaging section, (ii) an illumination device having a light-outputting end positioned in the imaging section for illuminating a region of the microvasculature with light, wherein the light-outputting end is offset relative to an optical axis of the imaging section; (iii) an objective lens positioned in the imaging section such that the objective lens receives at least a portion of light scattered by the region of the microvasculature, and (iv) an image detector positioned in the imaging section such that the image detector receives light redirected by the objective lens and detects microscopic images of the region of microvasculature.

92.

METHODS AND COMPOSITIONS FOR IMMUNE CELL CRISPR SCREENS

      
Application Number US2023067350
Publication Number 2023/230471
Status In Force
Filing Date 2023-05-23
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Maus, Marcela, V.
  • Manguso, Robert

Abstract

in vivo in vivo.

IPC Classes  ?

  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 15/867 - Retroviral vectors
  • C12Q 1/6869 - Methods for sequencing
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N 9/22 - Ribonucleases

93.

NEGATIVE PRESSURE LASER HANDPIECE

      
Application Number US2023067560
Publication Number 2023/230615
Status In Force
Filing Date 2023-05-26
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor Anderson, Richard, R.

Abstract

Disclosed are devices and methods for treating a skin condition (e.g., cutaneous neurofibroma tumors) of a subject. The device comprises: a chamber having an end wall, a side wall extending away from the end wall, and an opening opposite the end wall, wherein the side wall terminates in a contact surface for sealing against skin of a subject; a vacuum source in fluid communication with the interior space of the chamber, the vacuum source being structured to create negative pressure in the chamber; and a light source for irradiating a region of the skin of the subject with light, the light source being selected from the group consisting of laser light sources and wavelength-filtered light sources, the light source being positioned to direct the light at the region of the skin of the subject when the light source is activated to treat the skin condition.

IPC Classes  ?

  • A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
  • A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
  • A61N 5/067 - Radiation therapy using light using laser light

94.

TREATMENT AND DETECTION OF CANCERS HAVING A NEURAL-LIKE PROGENITOR, SQUAMOID/BASALOID/MESENCHYMAL, OR CLASSICAL PHENOTYPE

      
Application Number US2023067607
Publication Number 2023/230632
Status In Force
Filing Date 2023-05-30
Publication Date 2023-11-30
Owner
  • THE GENERAL HOSPITAL CORPORATION (USA)
  • DANA-FARBER CANCER INSTITUTE, INC. (USA)
  • MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
  • Hwang, William
  • Guo, James
  • Aguirre, Andrew
  • Jacks, Tyler
  • Su, Jennifer
  • Shiau, Carina

Abstract

The subject matter disclosed herein is generally directed to methods of detecting treatment refractory cancer and treatment thereof In example embodiments, specific biomarkers expressed specifically in pancreatic cancer subtypes are disclosed. The biomarkers can be used for therapeutic targeting of pancreatic cancers. The biomarkers can be used for noninvasive diagnostic methods.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 35/00 - Antineoplastic agents
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12Q 1/6844 - Nucleic acid amplification reactions
  • C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

95.

PHOTONIC ANTIMICROBIAL WOUND SURFACE DRESSING

      
Application Number US2022078479
Publication Number 2023/229659
Status In Force
Filing Date 2022-10-21
Publication Date 2023-11-30
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Gelfand, Jeffrey, A.
  • Anderson, Richard, Rox
  • Negri, Laisa, Bonafim
  • Farinelli, William, A.
  • Korupolu, Sandeep
  • Tam, Joshua

Abstract

Devices and methods for improving the infection-healing behavior of a biological wound are disclosed. The device can comprise: a matrix; a light-emitting layer comprising a plurality of light sources; a controller in electrical communication with the light sources, the controller being configured to execute a program stored in the controller to activate the light sources to irradiate the wound or a region adjacent the wound with light for a period of time when the device is placed over the wound; and an antimicrobial adjuvant present as part of the device in an amount effective to synergistically potentiate antimicrobial activity of the light with respect to microbes on or adjacent the wound. The wound may include microbes in a biofilm. In one embodiment, the antimicrobial adjuvant comprises a substituted naphthalene, such as menadione. In one embodiment, the antimicrobial adjuvant comprises near infrared radiation.

IPC Classes  ?

96.

INTRANASAL ADMINISTRATION OF POLYSULFIDE

      
Application Number US2023022917
Publication Number 2023/225305
Status In Force
Filing Date 2023-05-19
Publication Date 2023-11-23
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ichinose, Fumito
  • Kanemaru, Eiki

Abstract

Methods and devices for the nasal administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.

IPC Classes  ?

  • A61K 38/06 - Tripeptides
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link

97.

PHYSISORPTION OF ANTIBODIES ON FILMS

      
Application Number US2023022054
Publication Number 2023/220377
Status In Force
Filing Date 2023-05-12
Publication Date 2023-11-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Im, Hyungsoon
  • Kim, Kihyeun

Abstract

The present disclosure relates to direct immobilization of antibodies by physisorption onto plain and nanostructured metal-containing films. An exemplary method for preparing a sensor includes contacting an antibody with a surface of a film comprising an ionic compound and a metal selected from gold, silver, platinum, copper, and any combination thereof, and then contacting a blocking agent with the surface of the film to form the sensor.

IPC Classes  ?

  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

98.

SYSTEMS AND METHODS FOR SORTING USING LASER PARTICLES OR CELLS

      
Application Number US2023066490
Publication Number 2023/220536
Status In Force
Filing Date 2023-05-02
Publication Date 2023-11-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Yun, Seok-Hyun
  • Dannenberg, Paul

Abstract

A system and method for flow sorting includes a sample loader that is configured to receive a sample that contains one or more laser microparticles, wherein each laser microparticle is configured to generate laser emission with one or more distinct spectral peaks when excited. The system further includes a spectrometer receiving the laser emission from the one or more laser microparticle and generating spectral data and a processor configured to receive the spectral data and generate a sorting signal. The system also includes a switch configured to receive the sorting signal and route the one or more microparticles to a particular one of multiple collection channels based on the sorting signal.

IPC Classes  ?

99.

METHODS AND COMPOSITIONS FOR TISSUE REGENERATION

      
Application Number US2023066859
Publication Number 2023/220664
Status In Force
Filing Date 2023-05-11
Publication Date 2023-11-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Ott, Harald, C.
  • Jeffs, Sydney, E.
  • Altalhi, Wafa

Abstract

Disclosed is a method for regenerating and/or repairing lung tissue in a subject. The method comprises administering to a subject in need of lung tissue regeneration and/or repair a composition including (i) a carrier comprising a scaffold-forming material, (ii) cellular material selected from the group consisting of endothelial cells, epithelial cells, mesenchymal stem cells, and mixtures thereof, and (iii) pneumocytes. In one embodiment of the method, the administering is intravenously or intratracheally. The administering can be via airways to the lung. The scaffold-forming material can comprise (i) a first biopolymer having a first reactive group; (ii) a second biopolymer having a second reactive group, wherein the first reactive group and the second reactive group react via click chemistry to crosslink the first biopolymer and the second biopolymer to form a hydrogel; (iii) a porogen; and a (iv) porogen-degrading agent.

IPC Classes  ?

  • A61K 35/42 - Respiratory system, e.g. lungs, bronchi or lung cells
  • A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

100.

NANOPARTICLE DOPED POLYETHYLENE GLYCOL BASED GELS AND MEDICAL DEVICES FOR DRUG DELIVERY

      
Application Number US2023066936
Publication Number 2023/220717
Status In Force
Filing Date 2023-05-12
Publication Date 2023-11-16
Owner THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
  • Oral, Ebru
  • Asik, Mehmet, D.
  • Muratoglu, Orhun

Abstract

Provided herein are compositions, kits, and methods of making biodegradable compositions for localized drug delivery. The drug delivery compositions include one or more therapeutic agents that are dispersed within polymerized macromers of the drug delivery composition, loaded within biopolymeric nanoparticles within the drug delivery composition, or both. The release profiles of the one or more therapeutic agents are tunable based on the one or more therapeutic agents for a desired application.

IPC Classes  ?

  • C08J 3/075 - Macromolecular gels
  • A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
  • A61L 27/52 - Hydrogels or hydrocolloids
  • A61L 27/54 - Biologically active materials, e.g. therapeutic substances
  • A61L 27/58 - Materials at least partially resorbable by the body
  • A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  1     2     3     ...     22        Next Page